Home

Insights

PE

Kobo Biotech Ltd P/E Ratio

Kobo Biotech Ltd P/E Ratio

download
stocks purchased

₹ 0.0 Cr

Volume transacted

stocks purchased

12.7 K

stocks traded

Last Updated time: 12 Jul 9.00 AM

Image

Kobo Biotech Ltd

NSE: KOBOBIOTECH

PE

0

Last updated : 12 Jul 9.00 AM

Key Highlights

    The P/E Ratio of Kobo Biotech Ltd is 0 as of 12 Jul 9.00 AM .a1#The P/E Ratio of Kobo Biotech Ltd changed from 0 on March 2019 to 0 on March 2023 . This represents a CAGR of 0.0% over 5 years. a1#The Latest Trading Price of Kobo Biotech Ltd is ₹ 4.24 as of 12 Jul 15:30 .a1#The PE Ratio of Pharmaceuticals Industry has changed from 28.5 to 27.2 in 5 years. This represents a CAGR of -0.93%a1# The PE Ratio of Automobile industry is 17.2. The PE Ratio of Finance industry is 24.7. The PE Ratio of IT - Software industry is 29.3. The PE Ratio of Pharmaceuticals industry is 37.3. The PE Ratio of Retail industry is 143.1. The PE Ratio of Textiles industry is 12.1. In 2024a1#The Market Cap of Kobo Biotech Ltd changed from ₹ 10.96 crore on March 2019 to ₹ 4.53 crore on March 2023 . This represents a CAGR of -16.20% over 5 years. a1#The Revenue of Kobo Biotech Ltd changed from ₹ 0.02 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% a1#The EBITDA of Kobo Biotech Ltd changed from ₹ -0.32 crore to ₹ -0.25 crore over 8 quarters. This represents a CAGR of -11.61% a1#The Net Pr of Kobo Biotech Ltd changed from ₹ -1.47 crore to ₹ -1.26 crore over 8 quarters. This represents a CAGR of -7.42% a1#The Dividend Payout of Kobo Biotech Ltd changed from 0 % on March 2019 to 0 % on March 2023 . This represents a CAGR of 0.0% over 5 years. a1#

Open Demat Account

Lead form image

Enter your mobile no. to continue

+91

*By signing up you agree to our terms & conditions

50 Years

of Trust & Legacy

₹0 AMC

for First Year

₹0 Brokerage

on Delivery, Intraday, Currency and NSE F&O

×

Historical P/E Ratio of Kobo Biotech Ltd

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share. P/E Ratio Formula P/E ratio = (CMP of share/ Earning per share) Types of Price to Earning Ratio 1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance. 2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

Historical P/E Ratio of Kobo Biotech Ltd

Period
Mar '190
Mar '200
Mar '210
Mar '220
Mar '230

Company Fundamentals for Kobo Biotech Ltd

Market Cap

10 Cr

EPS

0.0

P/E Ratio (TTM) *

0.0

P/B Ratio (TTM) *

0.0

Day’s High

4.24

Day’s Low

4.2

DTE *

-1.1

ROE *

3.7

52 Week High

6.01

52 Week Low

2.05

ROCE *

-72.7

* All values are consolidated

Last Updated time: 12 Jul 9.00 AM

* All values are consolidated

Last Updated time: 12 Jul 9.00 AM

Image

Kobo Biotech Ltd

NSE: KOBOBIOTECH

PRICE

4.24

0.20 (4.95%)

stock direction

Last updated : 12 Jul 15:30

×

PRICE

The current market price or CMP refers to the price at which the securities are trading in the share market. Current price in Over-the-counter costs: The following current price depends upon the bid price & the asking price when a financial asset is sold over-the-counter(OTC). Current Price in Bond Market: The current price of a bond is determined by measuring the actual interest rate against the bid-related interest rate. The par or the face value is then calculated to represent the remaining interest payments due which occur before the maturity of the bond.

Share price Over Time

1M

1Y

3Y

5Y

* All values are in Rupees

SWOT Analysis Of Kobo Biotech Ltd

Strength

1

S

Weakness

1

W

Opportunity

0

O

Threats

0

T

Asset Value vs Market Value of Kobo Biotech Ltd

Market Value

10

-0.7 X

Value addition

Asset Value

38

* All values are in Rupees

Competitive Comparison of P/E Ratio

Company NamePEMarket Cap (INR Cr.)
Kobo Biotech Ltd010
Sun Pharmaceuticals Industries Ltd37378,675
Cipla Ltd28122,093
Divis Laboratories Ltd75120,480
Zydus Lifesciences Ltd30118,217
Dr Reddys Laboratories Ltd20112,137

Key Valuation Metric of Kobo Biotech Ltd

Earnings

-4 Cr

0.0 X

PE Ratio

Market Cap

₹10.1Cr

PE Ratio

PS Ratio

PB Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

Earnings

-4 Cr

0.0 X

PE Ratio

Market Cap

₹10.1Cr

PE Ratio

PS Ratio

PB Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

PE Ratio of Pharmaceuticals Industry over time

PE Ratio of Top Sectors

×

Historical Market Cap of Kobo Biotech Ltd

Market Cap or market capitalisation refers to metrics that are used to measure a company's size. It is defined as the total market value of a company's outstanding shares of stock. Formula of Market Cap: Market Capital = N * P Here, N for the outstanding shares P refers to the closing price of the company's shares. Types of Companies based on Market Cap: - Small-Cap stocks: Up to 500 Crore - Mid-Cap Stocks: From Rs.500 crore up to Rs.7,000 crore - Large-Cap Stocks: From Rs.7,000 crore up to Rs.20,000 crore

Historical Market Cap of Kobo Biotech Ltd

Period
Mar '1911
Mar '207
Mar '2118
Mar '2213
Mar '235

* All values are a in crore

×

Historical Revenue of Kobo Biotech Ltd

Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services. Types of Revenue: 1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered. 2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees. Formula for Revenue: The formula for calculating revenue is based on two goods & services: For goods: Revenue = Avg unit price x Number of Units sold For services: Revenue = Avg unit price x Number of Customers served.

Historical Revenue of Kobo Biotech Ltd

Period
Jun '220
Sep '220
Dec '220
Mar '230
Jun '230
Sep '230
Dec '230
Mar '240

* All values are a in crore

×

Historical EBITDA of Kobo Biotech Ltd

PBIDT stands for Profit Before Interest, Depreciation, and Taxes. It is a financial metric that measures a company's profitability before accounting for interest expenses, depreciation of assets, and taxes. Formula to calculate PBIDT: PBIDT = Net Income + Interest + Depreciation + Taxes or PBIDT = Operating Income + Depreciation + Taxes PBIDT vs EBITDA vs EBIT vs EBT: Here is a brief explanation of the differences: - PBIDT (Profit Before Interest, Depreciation, and Taxes) includes taxes in its calculation, unlike EBITDA. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) excludes taxes and interest, focusing on operational performance. - EBIT (Earnings Before Interest and Taxes) excludes interest and taxes, providing a measure of core operational profitability. - EBT (Earnings Before Taxes) includes all operating income but does not account for interest expenses. Conclusion: PBIDT, similar to EBITDA, is a measure of operational profitability but includes taxes in its calculation.

Historical EBITDA of Kobo Biotech Ltd

Period
Jun '220
Sep '220
Dec '220
Mar '23-1
Jun '230
Sep '230
Dec '230
Mar '240

* All values are a in crore

×

Historical Net Profit of Kobo Biotech Ltd

Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions. Net Profit formula is expressed as: Net Profit = Total Revenue - Total Expense Net Profit Margin Ratio: Net Profit Margin Ratio = Net Profit / Total Revenue

Historical Net Profit of Kobo Biotech Ltd

Period
Jun '22-1
Sep '22-1
Dec '22-1
Mar '23-2
Jun '23-1
Sep '23-1
Dec '23-1
Mar '24-1

* All values are a in crore

×

Historical Dividend Payout of Kobo Biotech Ltd

Dividend payout refers to the total dividends paid to shareholders relative to the company's earnings. It is a financial measure that determines the percentage of earnings paid out to existing shareholders as dividends. How to calculate Dividend Payout Ratio? The dividend payout ratio formula is as follows: DPR = Dividends paid / Net earnings With the dividend payout ratio, you can understand the company's priorities. It is an important metric that allows you to easily check DPR online.

Historical Dividend Payout of Kobo Biotech Ltd

Period
Mar '190
Mar '200
Mar '210
Mar '220
Mar '230

* All values are a in %

About Kobo Biotech Ltd

About Kobo Biotech Ltd

    Kobo Biotech Ltd.(Formerly known Avon Lifesciences Ltd) was established as a Public Limited Company on August 3, 1992. Effective 19th October, 2020, the Company's name was changed to Kobo Biotech Limited from erstwhile Avon Lifesciences Limited. The Company is a customer-centric manufacturer of active pharmaceutical ingredients (API).Promoted by P R Agarwal, Rajesh Agarwal and G S Sidhu, the Company manufacture diketene and its derivatives Monomethyl Acetoncetamide(MMA) and Methyl Acetoacetate(MAA). The company's 1200 tpa Diketene manufacturing faciltiy located at Sadashivpet in Andhrapradesh and the products of it were used in pigments, pharmaceuticals and pesticides. The company has a tripartite technical knowhow agreement with Shanghai Machinery & Equipment Import and Export Corporation (SMEC), representative of Shanghai Peng Pu Chemical Works (SPCW) and Xytel Technologies Partnership (XTP), US. XTP shall be the technical supervisor for the transfer of technology, while SMEC shall supply the technical knowhow. The company has bagged the award for the Best New Product manufactured in the State of Andhra Pradesh as awarded by the Federation of Andhra Pradesh Chamber of Commerce and Industry and also certified as an ISO 9002 company by American Quality Asseassors accredited with ANSI-RAB for the manufacturing and marketing MMAA, MMAE, DEA, EEAA and Aralydes. The company had developed technology for recovery of Diketene from sludge. The company has also diversified into Bio-Technology, where the value addition is high. To part finance its biotech project the company has made a preferential issue of 1800000 Equity shares at Rs. 38.75 each aggregating to Rs. 697.50 lacs and issued 400000 warrants convertible into 400000 equity shares during the year 1999-2000. The Bio-Technology Plant is located at Solapur,Maharashtra for manufacture of Ephedrine and Pseudo-Ephedrine with an installed capacity of 150 MT p.a. The plant has commenced operations during April 2001. The biotech division produces Pharmaceutical intermediates i.e Pseudoephedrine and ephedrine. The company has signed two longterm export contracts to supply fixed quantities of Pseudoephedrine and is in talks with a few more MNC's for long term contracts during the year 2001-02. The company's bio-tech division is pursuing USFD approval which will enable it to enter into regulated markets. The company is all set to introduce two high value added intermediates in its Diketene Division.The company has already completed trial production for these two pharmaceutical products and is ready for commercial launch.The company is expected an additional turnover of Rs.12 crores from these products from the year 2005-06. During the year 2004-05, the Company increased its production capacity in Biotech Division. Further the company has increased the storage capacity of molasses from 2000 tons to 6000 tons. The Company in 2006-07 had received USFDA approval for its facilities at Biotech Division, at Solapur, Maharashtra for manufacture of Psuedoephedrine. Pursuant to the preferential issue of 98,09,100 equity shares [43.60% of the total paid-up equity share capital] of the Company to Arch Pharmalabs Limited in November, 2007, the SEBI [Substantial Acquisition of Shares and Takeovers] Regulations, 1997 were attracted and accordingly Arch Pharmalabs Limited, a Mumbai based Company engaged in business of manufacturing Pharmaceutical Intermediates and Active Pharmaceutical Ingredients, was obligated to acquire upto 45,00,000 equity shares of Rs.10/- each representing 20% of the share capital of the Company. Further, on receipt of SEBI approval for the Open Offer vide SEBI letter dated 11th November, 2008, the Open Offer continued from 3rd December, 2008 till 22nd December, 2008. Pursuant to the closure of the Offer, 45,00,000 equity shares were accepted in the Open Offer at an offer price of Rs. 21.85 for each equity share and subsequently transferred to Arch Pharmalabs Limited, on 31 January, 2009. Post-transfer, the shareholding of Arch Pharmalabs Limited in the Company was 1,43,09,100 equity shares comprising 63.60% of the total equity capital of the Company. Pursuant to Arch Pharmalabs Limited acquiring a majority stake of 63.60% in the Company, the Company became a subsidiary of Arch Pharmalabs Limited. Regal Pharma PTE Ltd. was formed as wholly owned subsidiary company in Singapore on May 15, 2010.

Kobo Biotech Ltd News Hub

News

Kobo Biotech to convene board meeting

Kobo Biotech will hold a meeting of the Board of Directors of the Company on 30 May 2024 P...

Read more

28 May 202415:31

News

Kobo Biotech to conduct board meeting

Kobo Biotech will hold a meeting of the Board of Directors of the Company on 14 February 2...

Read more

09 Feb 202414:57

News

Kobo Biotech to hold board meeting

Kobo Biotech will hold a meeting of the Board of Directors of the Company on 10 November 2...

Read more

03 Nov 202317:17

News

Kobo Biotech to hold AGM

Kobo Biotech announced that the 30th Annual General Meeting (AGM) of the company will be h...

Read more

09 Sep 202318:44

News

Kobo Biotech to declare Quarterly Result

Kobo Biotech will hold a meeting of the Board of Directors of the Company on 11 August 202...

Read more

07 Aug 202313:02

News

Kobo Biotech to convene board meeting

Kobo Biotech will hold a meeting of the Board of Directors of the Company on 30 May 2023. ...

Read more

26 May 202315:22

Product Composition by Percentage (Revenue)

FAQs for PE of Kobo Biotech Ltd

What is Kobo Biotech Ltd current share price?

The current market price of Kobo Biotech Ltd as of July 12, 2024 is ₹4.24.

What is Kobo Biotech Ltd's market cap?

Kobo Biotech Ltd's market capitalisation stood at ₹10 Cr as of July 12, 2024

What are Kobo Biotech Ltd's total net assets?

According to Kobo Biotech Ltd's most recent financial filings, the company's net assets total ₹37.7 Cr.

Is Kobo Biotech Ltd making a profit or loss?

Kobo Biotech Ltd's net Profit as of July 12, 2024 is close to ₹-4 Cr.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199